Trials / Recruiting
RecruitingNCT06944457
Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor
A Phase I, Open-label, Single-center, Dose-escalation and Dose-finding Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Pharosgen Co.,Ltd · Industry
- Sex
- All
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I, Open-label, Single-center, Dose-escalation and Dose-finding Clinical trial to evaluate the safety, tolerability and pharmacokinetics of MPD-1 in patients with advanced solid tumor
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MPD-1 | It is a prodrug that uses Doxorubicin to target KRAS mutant/ PTEN loss advanced cancer. |
Timeline
- Start date
- 2024-12-10
- Primary completion
- 2026-12-31
- Completion
- 2027-06-30
- First posted
- 2025-04-25
- Last updated
- 2025-04-25
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06944457. Inclusion in this directory is not an endorsement.